Immuneering Corporation (IMRX)

US — Healthcare Sector
Peers: OLMA  NVCT  LRMR  CNTA  OBIO  RXST  CTKB  RPID  TRML 

Automate Your Wheel Strategy on IMRX

With Tiblio's Option Bot, you can configure your own wheel strategy including IMRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMRX
  • Rev/Share 0.0202
  • Book/Share 0.8041
  • PB 8.7054
  • Debt/Equity 0.1383
  • CurrentRatio 3.7032
  • ROIC -1.924

 

  • MktCap 254116366.0
  • FreeCF/Share -1.4321
  • PFCF -4.9309
  • PE -4.0545
  • Debt/Assets 0.0999
  • DivYield 0
  • ROE -1.4628

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade IMRX Morgan Stanley Equal Weight Underweight -- -- Dec. 13, 2024

News

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst
IMRX
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive

Immuneering Corporation is upgraded to a Strong Buy due to positive phase 2a data for atebimetinib in 1st-line RAS-mutant pancreatic cancer. IMRX's atebimetinib plus mGnP achieved superior 9-month overall survival (86%) and progression-free survival (53%) compared to standard of care. Key catalysts include expected FDA feedback in Q4 2025, potential phase 3 initiation by end of 2025, and expansion into other solid tumors and NSCLC.

Read More
image for news Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
IMRX
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

Read More
image for news Immuneering Stock Rises 21.7% on Supply Agreement With LLY
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
IMRX
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer.

Read More
image for news Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

About Immuneering Corporation (IMRX)

  • IPO Date 2021-07-30
  • Website https://immuneering.com
  • Industry Biotechnology
  • CEO Benjamin J. Zeskind
  • Employees 54
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.